According to the European Patent Office, Cellmid holds various patents, or to be more precise various patent families, within two different groups. Some, we are informed, have been licensed to Lyramid. Others are held by Advangen. One of the latter relates to Midkine.
Some details here -
METHOD OF TREATMENT OR PREVENTION OF HAIR LOSS OR FOR THE ENHANCEMENT OF HAIR GROWTH
Pat No: WO2011103624A1
Applicant : ADVANGEN INTERNAT PTY LTD
Inventors: Halasz Maria, Jones Darren, Sakuma Sadatoshi
Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.
Priority Date - 24 Feb 2010
At an AGM a couple of years ago the question was asked as to whether or not this particular patent family would go to Lyramid or stay with Advangen. The reply was that it would stay with Advangen.
So not "all midkine related patents" may in fact have been licensed to Lyramid.
poorinvestor
- Forums
- ASX - By Stock
- AN1
- Ann: Agreement Signed for Sale of Lyramid Limited
Ann: Agreement Signed for Sale of Lyramid Limited, page-263
-
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online